|
EP3569612A1
|
|
Treatment and prevention of house dust mite allergies
|
|
EP3295956A1
|
|
Polypeptide construct comprising fragments of allergens
|
|
EP3138579A1
|
|
Fusion protein for use in the treatment of a hepatitis b virus infection
|
|
WO2015070925A1
|
|
Fusion proteins
|
|
AU2013257437A1
|
|
Peptides derived from the major allergen of ragweed (ambrosia artemisiifolia) and uses thereof
|
|
EP2778681A1
|
|
Method for diagnosing a viral infection
|
|
WO2012168487A1
|
|
Peptide carrier fusion proteins as allergy vaccines
|
|
EP2664624A1
|
|
Allergen variants
|
|
EP2607376A1
|
|
Hypoallergenic allergen derivatives of Pru p 3 for immunotherapy of IgE-mediated peach allergy
|
|
EP2543725A1
|
|
Polysaccharide lyases
|
|
EP2460824A1
|
|
Hypoallergenic polypeptides for the treatment of house dust mite allergy
|
|
CA2778540A1
|
|
Pharmaceutical composition for the treatment and prevention of a rhinovirus infection
|
|
EP2316481A1
|
|
Pharmaceutical composition for the treatment and prevention of a rhinovirus infection
|
|
EP2295076A1
|
|
Hypoallergenic hybrid polypeptides for the treatment of allergy
|
|
EP2295972A1
|
|
S. aureus allergen
|
|
EP2110383A1
|
|
Hypoallergenic variants
|
|
EP2078960A1
|
|
Method for determining the type of allergy
|
|
EP2042193A1
|
|
RNA Vaccines
|
|
EP2028188A1
|
|
Hypoallergenic molecules
|
|
EP2000531A1
|
|
Antigen presenting cells
|
